15 research outputs found
A busca de informação na Internet: um estudo do comportamento de bibliotecários e estudantes de ensino médio
Potencial cicatricial da Bixa orellana L. em feridas cutâneas: estudo em modelo experimental
Imunização contra Hepatite B em crianças de zona endêmica: avaliação da resposta de anticorpo à vacina HB recombinante (Engerix B-20mcg)
A previous seroepidemiological study in the rural zone of Vargem Alta (ES) SouthEast of Brazil, showed a prevalence of up to 9% of hepatitis B surface antigen (HBsAg) in some areas. One hundred susceptible children aging 1 to 5 years old were selected and immunized with a recombinant DNA hepatitis B vaccine (Smith-Kline 20 mcg) using the 0-1-6 months vaccination schedule. Blood samples were collected at the time of the first vaccine dose (month 0) in order to confirm susceptible individuals and 1,3,6 and 8 months after the first dose , to evaluate the antibody response. Our results showed that two and five months after the second dose, 79% and 88% of children seroconverted respectively, reaching 97% after the third dose. The levels of anti-HBs were calculated in milli International Units/ml (mIU/ml) and demonstrated the markedly increase of protective levels of antibodies after the third dose. These data showed a good immunogenicity of the DNA recombinant hepatitis B vaccine when administered in children of endemic areas.Um estudo soroepidemiológico prévio na zona rural de Vargem Alta (ES) - Sudeste do Brasil, mostrou uma predominância de até 9% do antígeno de superfície da Hepatite B (HBsAg). Foram selecionadas 100 crianças com faixa etária entre 1 e 5 anos de idade, as quais foram imunizadas com vacina contra Hepatite B -DNA recombinante (Smith-Kline,20 mcg) nos meses 0,1 e 6. Foram coletadas amostras de sangue antes da primeira dose da vacina (mês 0) para confirmação dos susceptíveis, e nos meses 1,3,6 e 8 após a vacinação para avaliação da resposta vacinai. Os resultados mostraram que 79 e 88% das crianças apresentaram soroconversão dois e cinco meses após a segunda dose respectivamente, atingindo 97% de soroconversão, após a 3a.dose. Os níveis de anti-HBs foram calculados em miliunidades internacionais/ml (mUI/ml), demonstrando um considerável aumento dos níveis de anticorpos protetores após a 3a. dose. Os resultados demonstraram uma boa imunogenicidade da vacina de DNA recombinante contra hepatite B, quando administradas em crianças de áreas endêmicas
Immunization aganist hepatitis B in children from endemic zone: evaluation of the antibody response against the DNA recombinant vaccine (Engerix B-20 mcg)
A previous seroepidemiological study in the rural zone of Vargem Alta (ES) SouthEast of Brazil, showed a prevalence of up to 9% of hepatitis B surface antigen (HBsAg) in some areas. One hundred susceptible children aging 1 to 5 years old were selected and immunized with a recombinant DNA hepatitis B vaccine (Smith-Kline 20 mcg) using the 0-1-6 months vaccination schedule. Blood samples were collected at the time of the first vaccine dose (month 0) in order to confirm susceptible individuals and 1,3,6 and 8 months after the first dose , to evaluate the antibody response. Our results showed that two and five months after the second dose, 79% and 88% of children seroconverted respectively, reaching 97% after the third dose. The levels of anti-HBs were calculated in milli International Units/ml (mIU/ml) and demonstrated the markedly increase of protective levels of antibodies after the third dose. These data showed a good immunogenicity of the DNA recombinant hepatitis B vaccine when administered in children of endemic areas